Limited Offer
Save 50% on book bundles
Immediately download your ebook while waiting for your print delivery. No promo code needed.
Updates in Pharmacologic Strategies in ADHD, An Issue of ChildAnd Adolescent Psychiatric Clinics of North America
- 1st Edition, Volume 31-3 - June 15, 2022
- Editors: Jeffrey H. Newcorn, Timothy E. Wilens
- Language: English
- Hardback ISBN:9 7 8 - 0 - 3 2 3 - 9 1 9 9 1 - 3
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 1 9 9 2 - 0
In this issue of Child and Adolescent Psychiatric Clinics, guest editors Drs. Jeffrey H. Newcorn and Timothy E. Wilens bring their considerable… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteIn this issue of Child and Adolescent Psychiatric Clinics, guest editors Drs. Jeffrey H. Newcorn and Timothy E. Wilens bring their considerable expertise to the topic of Updates in Pharmacologic Strategies in ADHD. Top experts in the field cover key topics such as PK of stimulants pharmacogenomics, stimulants, nonstimulants, neurotherapeutics, and more.
-
Contains 15 relevant, practice-oriented topics including special groups: ADHD+, such as mood/ dysregulation and disruptive behavior; SUD; autism; tics, Tourette syndrome, and anxiety; sleep; cardiovascular; college-aged; transitional-aged youth; adults; and more.
-
Provides in-depth clinical reviews on pharmacologic strategies in ADHD, offering actionable insights for clinical practice.
-
Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.
- Cover image
- Title page
- Table of Contents
- Copyright
- Contributors
- Forthcoming Issues
- Preface
- From Structural Disparities to Neuropharmacology: A Review of Adult Attention-Deficit/Hyperactivity Disorder Medication Treatment
- Key points
- Epidemiology
- Etiology
- Pathophysiology
- Neuropharmacology
- Discussion
- Clinics care points
- Financial disclosures
- Funding acknowledgements
- Measurement Informed Care in Attention-Deficit/Hyperactivity Disorder (ADHD)
- Key points
- Introduction
- ADHD interviews
- Broad-based symptom screening
- Targeted ADHD symptom assessment
- Functional outcome
- Measurement informed care with ADHD-related dimensions of outcome
- Summary
- Clinics care points
- Stimulants
- Key points
- Introduction
- History
- Methylphenidate extended-release
- Amphetamine extended-release
- Discussion
- Long-term treatment
- Summary
- Clinics care points
- The Pharmacokinetics and Pharmacogenomics of Psychostimulants
- Key points
- Introduction
- Pharmacodynamics
- Pharmacokinetics
- Summary
- Clinics care points
- Disclosure
- Nonstimulant Treatments for ADHD
- Key points
- Introduction/history/Definitions/Background
- Discussion
- Atomoxetine
- Investigational compounds
- Clinical use of nonstimulants
- Summary
- Clinics care points
- Disclosure
- Cardiovascular Considerations for Stimulant Class Medications
- Key points
- Background
- Current evidence
- Serious or rare cardiovascular events
- Guidelines and recommendations
- Controversies
- Complications/concerns
- Medical comorbidities
- Future directions
- Summary
- Clinics care points
- Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder
- Key points
- Introduction
- Approach
- Results
- Discussion
- Summary
- Clinics care points
- Pharmacologic Treatment of Comorbid Attention-Deficit/Hyperactivity Disorder and Tourette and Tic Disorders
- Key points
- Introduction
- Research and current evidence in pharmacotherapy for attention-deficit/hyperactivity disorder and tic disorders
- Discussion
- Summary
- Clinics care points
- Updates in Pharmacologic Strategies for Emotional Dysregulation in Attention Deficit Hyperactivity Disorder
- Key points
- Introduction
- Emotion dysregulation in attention deficit hyperactivity disorder
- Methods
- Results
- Discussion
- Summary
- Clinics care points
- Attention Deficit Hyperactivity Disorder Medications and Sleep
- Key points
- Introduction
- Prevalence of sleep problems in ADHD
- Methodological issues in clinical trials
- Stimulants and sleep problems
- Select populations
- Management of co-occurring sleep and ADHD
- Summary
- Clinics care points
- ADHD and Substance Use Disorders in Young People: Considerations for Evaluation, Diagnosis, and Pharmacotherapy
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Disclosure
- Addressing the Treatment and Service Needs of Young Adults with Attention Deficit Hyperactivity Disorder
- Key points
- Introduction
- Discussion
- Summary
- Clinics care points
- Updates in Pharmacologic Strategies in Adult Attention-Deficit/Hyperactivity Disorder
- Key points
- Introduction
- Nature of the problem
- Therapeutic options
- Future directions
- Summary
- Clinics care points
- A Review of Clinical Practice Guidelines in the Diagnosis and Treatment of Attention-Deficit/Hyperactivity Disorder
- Key points
- Introduction
- Defining clinical practice guidelines
- Determining the quality of clinical practice guidelines
- Overview of current attention-deficit/hyperactivity disorder clinical practice guidelines
- Impact of clinical practice guidelines on the quality of care
- Clinical practice guidelines and the standard of care
- Future research and directions
- Clinics care points
- No. of pages: 240
- Language: English
- Edition: 1
- Volume: 31-3
- Published: June 15, 2022
- Imprint: Elsevier
- Hardback ISBN: 9780323919913
- eBook ISBN: 9780323919920
JN
Jeffrey H. Newcorn
Affiliations and expertise
Professor of Psychiatry and Pediatrics, Director, Division of ADHD and Learning Disorders, Icahn School of Medicine at Mount Sinai, Director, Pediatric Psychopharmacology, Mount Sinai Health SystemTW
Timothy E. Wilens
Dr. Timothy Wilens is Chief of the Division of Child and Adolescent Psychiatry and is Co-director of the Center for Addiction Medicine at Massachusetts General Hospital (MGH). He is the MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry at Harvard Medical School (HMS). Dr. Wilens earned his MD at the University of Michigan Medical School in Ann Arbor and completed his residency in child, adolescent, and adult psychiatry at the MGH. Dr. Wilens’ research interests include the relationship among attention deficit/hyperactivity disorder (ADHD), bipolar disorder, and substance use disorders; embedded health care models; and the pharmacotherapy of ADHD across the lifespan. He has published more than 350 peer-reviewed articles concerning these and related topics. He has also co-edited more than 90 book chapters, 5 books, and 350 abstracts and presentations for national and international scientific meetings. Dr. Wilens is a distinguished fellow of the American Psychiatric Association and the American Academy of Child and Adolescent Psychiatry and serves on the board or as a scientific reviewer for more than 35 journals.
Affiliations and expertise
Chief of the Division of Child and Adolescent Psychiatry and Co-director of the Center for Addiction Medicine; Massachusetts General Hospital (MGH); MGH Trustees Chair in Addiction Medicine and Professor of Psychiatry, Harvard Medical School